Biogen Inc. $BIIB Shares Purchased by Leuthold Group LLC

Leuthold Group LLC increased its position in shares of Biogen Inc. (NASDAQ:BIIB) by 38.6% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 32,589 shares of the biotechnology company’s stock after purchasing an additional 9,072 shares during the quarter. Leuthold Group LLC’s holdings in Biogen were worth $5,735,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in Biogen by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 17,447,092 shares of the biotechnology company’s stock worth $3,070,514,000 after buying an additional 157,857 shares in the last quarter. Invesco Ltd. increased its stake in Biogen by 4.2% in the third quarter. Invesco Ltd. now owns 2,418,127 shares of the biotechnology company’s stock valued at $338,731,000 after purchasing an additional 98,001 shares during the last quarter. AQR Capital Management LLC grew its position in Biogen by 30.7% during the third quarter. AQR Capital Management LLC now owns 1,783,581 shares of the biotechnology company’s stock valued at $248,809,000 after acquiring an additional 418,776 shares during the period. Legal & General Group Plc grew its position in Biogen by 10.1% during the third quarter. Legal & General Group Plc now owns 1,593,399 shares of the biotechnology company’s stock valued at $223,203,000 after acquiring an additional 146,583 shares during the period. Finally, Pictet Asset Management Holding SA grew its position in Biogen by 22.9% during the fourth quarter. Pictet Asset Management Holding SA now owns 947,494 shares of the biotechnology company’s stock valued at $166,900,000 after acquiring an additional 176,639 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen said its Phase 2 CELIA study of diranersen (BIIB080), a tau-targeting Alzheimer’s drug, showed robust reductions in tau pathology and signals of slowed cognitive decline, prompting the company to advance the program into late-stage development. Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
• Positive Sentiment: Goldman Sachs reiterated a Buy rating and lifted its price target to $250, while Oppenheimer raised its target to $300 and Evercore initiated coverage with an Outperform rating, reinforcing optimism around Biogen’s valuation and pipeline. Goldman’s Richter Reiterates Buy on Biogen as Leqembi Outperforms and Price Target Rises from $238 to $250 Oppenheimer raises Biogen price target to $300 from $275, maintains Outperform rating
• Positive Sentiment: Biogen completed its $5.3 billion acquisition of Apellis Pharmaceuticals, adding commercial products SYFOVRE and EMPAVELI and potentially improving near-term growth prospects. Biogen Completes Acquisition of Apellis Pharmaceuticals
• Neutral Sentiment: Some analysts remain cautious, saying mixed Alzheimer’s data and pipeline uncertainty still create a balanced risk/reward profile despite the recent rally. Biogen: Hold Rating Reiterated as Pipeline Concerns Offset Leqembi Growth; $196 Price Target Maintained
• Negative Sentiment: The CELIA study missed its primary endpoint, and a law firm has already announced an investigation into possible securities-law issues tied to the stock’s move after the data release, which could add headline risk. Investigation Alert: Biogen Inc. (BIIB) Under Scrutiny – Contact Levi & Korsinsky for Details

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on BIIB shares. TD Cowen boosted their price target on Biogen from $175.00 to $215.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Canaccord Genuity Group boosted their price target on Biogen from $230.00 to $245.00 and gave the stock a “buy” rating in a research note on Wednesday, April 1st. Mizuho upped their price objective on Biogen from $207.00 to $236.00 and gave the company an “outperform” rating in a research note on Tuesday, February 10th. JPMorgan Chase & Co. upped their price objective on Biogen from $175.00 to $185.00 and gave the company a “neutral” rating in a research note on Thursday, April 23rd. Finally, Wolfe Research set a $231.00 target price on Biogen in a report on Monday, February 9th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Biogen presently has a consensus rating of “Moderate Buy” and an average target price of $215.62.

Biogen Stock Performance

Shares of BIIB stock opened at $192.95 on Friday. The business has a 50 day simple moving average of $185.21 and a 200 day simple moving average of $179.33. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41. The firm has a market capitalization of $28.49 billion, a price-to-earnings ratio of 20.70, a price-to-earnings-growth ratio of 1.70 and a beta of 0.19. Biogen Inc. has a 12-month low of $121.05 and a 12-month high of $205.97.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.95 by $0.62. The firm had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The firm’s quarterly revenue was up 1.9% on a year-over-year basis. During the same period last year, the company posted $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, equities research analysts anticipate that Biogen Inc. will post 14.21 EPS for the current year.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.